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Identity 
Other names: DOM, MGC15649, WS2E, WS4 
HGNC (Hugo): SOX10 
Location: 22q13.1 
Local order: Flanked by POLR2F (DNA-directed 
RNA polymerase II polypeptide F) and PICK1 (protein 
interacting with PRKCA 1). 
DNA/RNA 
Note 
SOX10 was first identified as a gene mutated in 
patients suffering from Waardenburg syndrome type 
4C (WS4C). SOX10 mutations also cause 
Waardenburg syndrome type 2E (WS2E) with or 
without neurologic involvement, Yemenite deaf-blind 
hypopigmentation syndrome and PCWH syndrome. 
They usually occur in the heterozygous state and can be 
either sporadic or familial. 
Description 
DNA size: 12.22kb; 5 Exons. 
Transcription 
mRNA size: 2882 nucleotides. 
Protein 
Note 
The SOX10 protein belongs to subgroup E of the SOX 
protein family. All 20 human members of this protein 
family possess a high-mobility-group (HMG) domain 
with three alpha-helical regions and close similarity to 
the one found in the male sex determining factor SRY. 
SOX10 functions as transcription factor and structural 
protein in chromatin. SOX9 and SOX8 are its closest 
relatives among human SOX proteins. 
Description 
SOX10 consists of 466 amino acids. The following 
domains exist (from amino terminal to carboxy 
terminal): DNA-dependent dimerization domain 
(amino acids 61-101), DNA-binding HMG-domain 
(amino acids 101-180), context-dependent 
transactivation domain K2 (amino acids 233-306) and 
main transactivation domain TA (amino acids 400-
462). SOX10 possesses two nuclear localization signals 
(NLS) at the beginning and the end of the HMG 




The SOX10 gene with its 5 exons. The open reading frame (orange) is split between exons 3-5. The 5' untranslated region is generated 
from exons 1-3 and the 3' untranslated region corresponds to the hind part of exon 5. 
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Human SOX10 and its domains including the DNA-dependent dimerization domain (Dim), the DNA-binding HMG domain, the context-
dependent transactivation domain K2 and the main transactivation domain (TA). Numbers indicate amino acid positions. The bottom 
shows the exact amino acid sequence of the HMG domain with its three alpha-helices, the 2 nuclear localization signals (NLS1, NLS2) 
and the nuclear export sequence (NES). 
 
Expression 
SOX10 expression is first detected during embryonic 
development in the emerging neural crest and continues 
transiently or permanently in many non-
ectomesenchymal derivates of the neural crest 
including melanocytes, adrenal medulla and the 
developing peripheral nervous system. Within the 
developing central nervous system SOX10 marks cells 
of the oligodendrocyte lineage. In the adult, SOX10 is 
predominantly found in oligodendrocytes, peripheral 
glial cells, melanocytes and adult neural crest stem cell 
populations. 
Localisation 
SOX10 is predominantly found in the nucleus as 
expected for a transcription factor but possesses the 
ability to shuttle between cytoplasm and nucleus 
because of the presence of both NLS and NES in the 
protein. 
Function 
SOX10 has multiple roles during development. In 
neural crest stem cells, SOX10 is needed for self-
renewal, survival and maintenance of pluripotency. 
SOX10 is furthermore required for specification of 
melanocytes and peripheral glia from the neural crest. 
After specification, SOX10 continues to be essential for 
lineage progression and maintenance of identity in 
peripheral glia. Terminal differentiation of 
oligodendrocytes also depends on SOX10. SOX10 
exerts these functions through interactions with 
different sets of transcription factors. SOX10 probably 
shares further roles with its close relatives SOX9 and 
SOX8 with which it is co-expressed in several cell 
types and functions in a partly redundant manner. 
Homology 
SOX10 is highly conserved among vertebrates. Human 
SOX10 shares 98% identity with Mus musculus Sox10, 
97% identity with Sox10 from Rattus norvegicus and 
Canis lupus familiaris, 96% identity with Bos taurus 






SOX10 mutations have so far primarily been identified 
as a cause for neurocristopathies including WS4C, 
WS2E with or without neurologic involvement, PCWH 
syndrome and Yemenite deaf-bling hypopigmentation 
syndrome. 
Germinal 
Missense mutations: S135T, A157V, Q174P. 
Nonsense mutations: R43X, T83X, T173X, E189X, 
T207X, Q234X, Q250X, S251X, T313X, S346X, 
Q364X, Q372X, S376X, Q377X. 
Insertions: (L160 R161) dup. 
Carboxy terminal extensions: X467C ext82, X467L 
ext86, X467T ext86. 
Frameshift mutations: S17C fsX17, E57S fsX57, 
A110L fsX2, P169R fsX117, R215P fsX64, R261A 
fsX25, G266A fsX20, I271S fsX15, H283L fsX11, 
H306T fsX5, G308A fsX3, V350C fsX52, A354P 
fsX3, E359D fsX42, Q399V fsX2. 
Splice mutations: int3 pos.428 +2T>G, int4 pos.698 -
2A>C. 
Somatic 
Missense mutations: R43Q, Q125X, A361V, G413S, 
G413D, H414Y, A424V. 




SOX10 is expressed homogenously in primary and 
metastatic melanoma and was identified as a melanoma 
tumor antigen. It is often co-expressed with its relative 
SOX9. Somatic SOX10 mutations occur in early stage 
melanoma. SOX10 upregulates MITF, MET and Nestin 
expression in melanoma and responds to Wnt signals. 
Its nuclear localization is controlled by the Tam 
tyrosine receptor kinase Tyro3 and its activity is  
 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)  67 
modulated by the transcription factor SOX5. In sentinel 
lymph nodes, SOX10 is a reliable marker for metastatic 
melanoma. 
Clear cell sarcoma 
Note 
SOX10 is widely expressed in clear cell sarcoma where 
it cooperates with EWS-ATF1 fusions in MITF 
activation. 
Malignant nerve sheath tumor (MNST) 
Note 
SOX10 is present in MNST. Expression levels appear 
lower than the ones in plexiform neurofibromas from 
which MNST arise or in Schwann cells. SOX10 
expression levels are positively correlated with ErbB3 
levels and inversely correlated with SOX9 levels. 
Schwannoma 
Note 
Homogenous SOX10 expression has been detected 
throughout this neoplasm. 
Ganglioneuroma 
Note 
SOX10 expression has been detected. Levels decrease 
with increasing grade. 
Glioma 
Note 
SOX10 transcripts and protein were found in 
astrocytoma, oligodendroglioma and glioblastoma. 
Expression levels and number of expressing cells 
within the tumor usually diminish with advancing 
grade and malignant progression. SOX10 levels are 
particularly high in pilocytic astrocytoma. No 
correlation with 1p and 19q deletions has been 
detected. In a mouse model, SOX10 has been found to 
act synergistically with PDGF during glioma 
development, although it was not sufficient to induce 
gliomagenesis on its own. 
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